Ototoxicity Induced by Cisplatin – Clinical Observation and Determination of Individual Sensitivity
Authors:
T. Talach 1; R. Kostřica 1; J. Rottenberg 1; M. Jurajda 2; I. Kocák 3; R. Lakomý 3
Authors‘ workplace:
Klinika ORL a chirurgie hlavy a krku LF MU a FN U sv. Anny, Brno, přednosta prof. MUDr. R. Kostřica, CSc. 1, Ústav patologické fyziologie LF MU, Brno2, KKOP MOÚ a LF MU, Brno
3
Published in:
Otorinolaryngol Foniatr, 59, 2010, No. 4, pp. 175-179.
Category:
Original Article
Overview
The clinical manifestation of ciplatin (CDDP) induced ototoxicity comprises unilateral or bilateral sensorial hearing loss (reversible or permanent) and tinnitus. The ototoxicity was shown to depend more on the individual sensitivity than on the total dose applied. The aim of the pilot study was to test (A) the effect of variable doses of CDDP and (B) efficiency of various diagnostic methods using three groups of patients. Otoacoustic emissions exhibited better predictive potential for final ototoxicity severity than classical tone audiometry. Presence of tinnitus did not predict degree of hearing loss. Based on the pilot study patients with the testicular and extragonadal germline tumors treated with CDDP were selected as an optimal study group for subsequent larger scale study. Apart from disease and treatment related parameters individual sensitivity will be assessed using genotyping of selected genetic markers in candidate genes related to oxidative/antioxidative balance.
Key words:
ototoxicity, cisplatin, otoacoustic emissions, tone audiometry, sensory-neural hearing loss.
Sources
1. Bauer, C. A., Brozoski, T. J.: Cochlear structure and function after round window application of ototoxins. Hear Res., 201, 2005, 1-2, s. 121-31.
2. Berg, A. L., Spitzer, J. B., Gardin, J. H.: Ototoxic impact of cisplatin in pediatric oncology patients. Laryngoskope, 109, 1999, s. 1806-1814.
3. Bertolini, P., Lassalle, M., Mercier, G., Raquin, M. A., Izzi, G., Corradini, N., Hartmann, O.: Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J. Pediatr. Hematom. Oncol., 26, 2004, 10, s. 649-655.
4. Domenech, J., Carulla, M., Traserra, J.: Tinnitus in the diagnosis and prognosis of ototoxicity. Acta Otorrinolaringol Esp., 41, 1990, 1, s. 7-9.
5. Dreschler, W. A., Hulst, R. J., Tange, R. A., Urbanu, N. A.: The role of high-frequency audiometry in early detection of ototoxicity. Audiology, 24, 1985, 6, s. 387-395.
6. Fetoni, A. R., Sergi, B., Ferraresi, A., Paludetti, G., Trojanu, D.: Protective effects of alpha-tocopherol and tiopronin against cisplatin-induced ototoxicity. Acta Otolaryngol, 124, 2004, 4, s. 421-426.
7. Ilveskoski, I., Saarinen, U. M., Wiklund, T., Perkkio, M., Salmi, T. T., Panniny, M., Makipernaa, A., Pihko, H.: Ototoxicity in children with malignant brain tumors treated with the “8 in 1” chemotherapy protocol. Med. Pediatr. Oncol., 27, 1996, 1, s. 26-31.
8. Langer, T., Stohr, W., Bielack, S., Paulussen, M., Treuner, J., Beck, J. D.; German Late Effects Working Group in the German Society of Pediatric Oncology and Hematology: Late effects surveillance system for sarcoma patients. Pediatr. Blood Cancer, 42, 2004, 4, s. 373-379.
9. Laurell, G., Engstrom, B., Hirsch, A., Bagger-Sjoback, D.: Ototoxicity of cisplatin. Int. J. Androl., 10, 1987, 1, s. 359-362.
10. Li, Y., Womer, R. B., Silber, J. H.: Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J. Cancor,40, 2004, 16, s. 2445-2451.
11. Melamed, L. B., Selim, M. A., Schuchman, D.: Cisplatin ototoxicity in gynecologic cancer patients. A Preliminary Report. Cancer, 55, 1985, 1 s. 41-43.
12. Montaguti, M., Brandolini, C., Ferri, G. G., Hatzopoulos, S., Prete, A., Pension, A.: Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention. Acta Otorhinolaryngol Ital., 22, 2002, 1, s. 14-18.
13. Orts Alborch, M., Garcia Callejo, J., Morant Ventura, A., Ferrer Baixauli, F., Esparcia Navarro, M., Marco Algarra, J.: Clinical study on the ototoxicity of cisplatin with distortion products. Acta Otorrinolaringol Esp., 51, 2000, 6, s. 469-477.
14. Park, K. R.: The utility of acoustic reflex thresholds and other conventional audiologic tests for monitoring cisplatin ototoxicity in the pediatric population. Ear Hear, 17, 1996, 2, s. 107-115.
15. Pollera, C. F., Marolla. P., Nardi, M., Ameglio, F., Cozzo, L., Bevere, F.: Very high-dose cisplatin-induced ototoxicity: a preliminary report on early and long-term effects. Cancer Chemother. Pharmacol., 21, 1988, 1, s. 61-64.
16. Ramirez-Camacho, R., Garcia-Berrocal, J. R., Bujan, J., Martin-Marero, A., Trinidad, A.: Supporting cells as a target of cisplatin-induced inner ear damage: therapeutic implications. Laryngoskope, 114, 2004, 3, s. 533-537.
17. Ramirez-Camacho, R., Garcia-Berrocal, J. R., Trinidad, A., Martin-Marero, A., Bujan, J.: Cochlear cytotoxic activity of cisplatin in experimentation animals. A study using scanning electron microscopy. Acta Otorrinolaringol Esp., 53, 2002, 8, s. 538-542.
18. Ress, B. D., Sridhar, K. S., Balkany, T. J., Axman, G. M., Stagner, B. B., Lonsbury-Martin, B. L.: Effects of cis-platinum chemotherapy on otoacoustic emissions: the development of an objective screening protocol. Third place-Resident Clinical Science Award 1998. Otolaryngol Head Neck Surg., 121, 1999, 6, 693-701.
19. Sergi, B., Ferraresi, A., Trojanu, D., Paludetti, G., Fetoni, A. R.: Cisplatin ototoxicity in the guinea pig: vestibular and cochlear damage. Hear Res., 182, 2003, 1-2, s. 56-64.
20. Sockalingam, R., Filippech, L., Charles, B., Mudroch, B.: Cisplatin-induced ototoxicity and pharmacokinetics: preliminary findings in a dog model. Ann. Otol. Rhinol. Laryngol., 111, 2002, 8, s. 745-750.
21. Stavroulaki, P., Apostolopoulos, N., Pegas, J., Tsakanikos, M., Adamopoulos, G.: Evoked otoacoustic emissions—an approach for monitoring cisplatin induced ototoxicity in children. Int. J. Pediatr. Otorhinolaryngol, 59, 2001, 1, s. 47-57.
22. Toral-Martinon, R., Shkurovich-Bialik, P., Collado-Corona, M. A., Mora-Magana, I., Goldgrub-Listopad, S., Shkurovich-Zaslavsky, M.: Distortion product otoacoustic emissions test is useful in children undergoing cisplatin treatment. Arch. Med. Res., 34, 2003, 3, s. 205-208.
23. van der Hulst, R. J., Dreschler, W. A., Urbanu, N. A.: High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann. Otol. Rhinol. Laryngol., 97, 1988, 2, Pt 1, s. 133-137.
24. van Ruijven, M. W, de Groot, J. C., Smoorenburg, G. F.: Time sequence of degeneration pattern in the guinea pig cochlea during cisplatin administration. A quantitative histological study. Hear Res., 197, 2004, 1-2, s. 44-54.
25. Vodvarka, P., Foukalova, J., Mrazek, J., Philippova, J.: Ototoxicity of cis-diamminedichloroplatinum. Neoplasma, 32, 1985, 2, s. 229-238.
26. Watanabe, K., Jinnouchi, K., Žati, T.: Detection of single-stranded DNA (ssDNA) in the vestibule of guinea pigs after the application of cisplatinum (CDDP). Anticancer Res., 21, 2001, 2A, s. 1135-1138.
Labels
Audiology Paediatric ENT ENT (Otorhinolaryngology)Article was published in
Otorhinolaryngology and Phoniatrics
2010 Issue 4
Most read in this issue
- PFAPA Syndrome in Child ENT Area and Its Indication for Tonsillectomy
- Kawasaki Syndrome – Possible Cause of Cervical Lymphadenitis in Children
- Vestibular Evoked Myogenic Potentials – VEMP: Method Standardization
-
Obstructive Sleep Apnea – the Importance of Septoplasty and Turbinoplasty
Part II (Practical)